Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

16 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Management of non-metastatic castrate-resistant prostate cancer: A systematic review.
Loriot Y, Supiot S, Beauval JB, Schlürmann F, Pasticier G, Sargos P, Barthélémy P, Pignot G, Maillet D, Vincendeau S, Gross E, Ploussard G, Timsit MO, Borchiellini D. Loriot Y, et al. Among authors: schlurmann f. Cancer Treat Rev. 2018 Nov;70:223-231. doi: 10.1016/j.ctrv.2018.09.006. Epub 2018 Sep 21. Cancer Treat Rev. 2018. PMID: 30300771 Review.
Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 × 2 factorial design.
Fizazi K, Foulon S, Carles J, Roubaud G, McDermott R, Fléchon A, Tombal B, Supiot S, Berthold D, Ronchin P, Kacso G, Gravis G, Calabro F, Berdah JF, Hasbini A, Silva M, Thiery-Vuillemin A, Latorzeff I, Mourey L, Laguerre B, Abadie-Lacourtoisie S, Martin E, El Kouri C, Escande A, Rosello A, Magne N, Schlurmann F, Priou F, Chand-Fouche ME, Freixa SV, Jamaluddin M, Rieger I, Bossi A; PEACE-1 investigators. Fizazi K, et al. Among authors: schlurmann f. Lancet. 2022 Apr 30;399(10336):1695-1707. doi: 10.1016/S0140-6736(22)00367-1. Epub 2022 Apr 8. Lancet. 2022. PMID: 35405085 Clinical Trial.
Cabozantinib-nivolumab sequence in metastatic renal cell carcinoma: The CABIR study.
Vano YA, Phan L, Gravis G, Korakis I, Schlürmann F, Maillet D, Bennamoun M, Houede N, Topart D, Borchiellini D, Barthelemy P, Ratta R, Ryckewaert T, Hasbini A, Hans S, Emambux S, Cournier S, Braychenko E, Elaidi RT, Oudard S. Vano YA, et al. Among authors: schlurmann f. Int J Cancer. 2022 Oct 15;151(8):1335-1344. doi: 10.1002/ijc.34126. Epub 2022 Jun 6. Int J Cancer. 2022. PMID: 35603906 Free PMC article.
Oncological Outcomes of Delayed Nephrectomy After Optimal Response to Immune Checkpoint Inhibitors for Metastatic Renal Cell Carcinoma.
Pignot G, Thiery-Vuillemin A, Albigès L, Walz J, Lang H, Balssa L, Parier B, Geoffrois L, Bensalah K, Schlürmann F, Ladoire S, Bigot P, Borchiellini D, Cassuto O, Thibault C, Ingels A, Saldana V, Roubaud G, Bernhard JC, Gravis G, Barthélémy P. Pignot G, et al. Among authors: schlurmann f. Eur Urol Oncol. 2022 Oct;5(5):577-584. doi: 10.1016/j.euo.2022.07.002. Epub 2022 Jul 17. Eur Urol Oncol. 2022. PMID: 35853818
Abiraterone and Olaparib for Metastatic Castration-Resistant Prostate Cancer.
Clarke NW, Armstrong AJ, Thiery-Vuillemin A, Oya M, Shore N, Loredo E, Procopio G, de Menezes J, Girotto G, Arslan C, Mehra N, Parnis F, Brown E, Schlürmann F, Joung JY, Sugimoto M, Virizuela JA, Emmenegger U, Navratil J, Buchschacher GL, Poehlein C, Harrington EA, Desai C, Kang J, Saad F. Clarke NW, et al. Among authors: schlurmann f. NEJM Evid. 2022 Sep;1(9):EVIDoa2200043. doi: 10.1056/EVIDoa2200043. Epub 2022 Jun 3. NEJM Evid. 2022. PMID: 38319800
Feasibility Study and Preliminary Results of Prognostic Value of Bone SPECT-CT Quantitative Indices for the Response Assessment of Bone Metastatic Prostate Carcinoma to Abiraterone.
de Laroche R, Bourhis D, Robin P, Delcroix O, Querellou S, Malhaire JP, Schlurmann F, Bourbonne V, Salaün PY, Schick U, Abgral R. de Laroche R, et al. Among authors: schlurmann f. Front Med (Lausanne). 2020 Jan 22;6:342. doi: 10.3389/fmed.2019.00342. eCollection 2019. Front Med (Lausanne). 2020. PMID: 32039220 Free PMC article.
Olaparib plus abiraterone versus placebo plus abiraterone in metastatic castration-resistant prostate cancer (PROpel): final prespecified overall survival results of a randomised, double-blind, phase 3 trial.
Saad F, Clarke NW, Oya M, Shore N, Procopio G, Guedes JD, Arslan C, Mehra N, Parnis F, Brown E, Schlürmann F, Joung JY, Sugimoto M, Sartor O, Liu YZ, Poehlein C, Barker L, Del Rosario PM, Armstrong AJ. Saad F, et al. Among authors: schlurmann f. Lancet Oncol. 2023 Oct;24(10):1094-1108. doi: 10.1016/S1470-2045(23)00382-0. Epub 2023 Sep 12. Lancet Oncol. 2023. PMID: 37714168 Clinical Trial.
Efficacy and Safety of Olaparib Plus Abiraterone Versus Placebo Plus Abiraterone in the First-line Treatment of Patients with Asymptomatic/Mildly Symptomatic and Symptomatic Metastatic Castration-resistant Prostate Cancer: Analyses from the Phase 3 PROpel Trial.
Clarke NW, Armstrong AJ, Oya M, Shore N, Procopio G, Daniel Guedes J, Arslan C, Mehra N, Parnis F, Brown E, Schlürmann F, Young Joung J, Sugimoto M, Sartor O, Poehlein C, McGuinness D, Degboe A, Saad F. Clarke NW, et al. Among authors: schlurmann f. Eur Urol Oncol. 2024 Oct 8:S2588-9311(24)00222-0. doi: 10.1016/j.euo.2024.09.013. Online ahead of print. Eur Urol Oncol. 2024. PMID: 39384451 Free article.
16 results